EP1904110A4 - Targeting von zellen mit veränderter microrna-expression - Google Patents

Targeting von zellen mit veränderter microrna-expression

Info

Publication number
EP1904110A4
EP1904110A4 EP06741167A EP06741167A EP1904110A4 EP 1904110 A4 EP1904110 A4 EP 1904110A4 EP 06741167 A EP06741167 A EP 06741167A EP 06741167 A EP06741167 A EP 06741167A EP 1904110 A4 EP1904110 A4 EP 1904110A4
Authority
EP
European Patent Office
Prior art keywords
microrna expression
targeting cells
altered microrna
altered
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06741167A
Other languages
English (en)
French (fr)
Other versions
EP1904110A1 (de
Inventor
Michael Zenon Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICA
Original Assignee
SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTRE
SOUTHERN ADELAIDE HEALTH SERVI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTRE, SOUTHERN ADELAIDE HEALTH SERVI filed Critical SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTRE
Priority to EP11161737A priority Critical patent/EP2377559A1/de
Publication of EP1904110A1 publication Critical patent/EP1904110A1/de
Publication of EP1904110A4 publication Critical patent/EP1904110A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation
EP06741167A 2005-06-03 2006-06-02 Targeting von zellen mit veränderter microrna-expression Withdrawn EP1904110A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11161737A EP2377559A1 (de) 2005-06-03 2006-06-02 Targeting von Zellen mit veränderter microRNA-Expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68754705P 2005-06-03 2005-06-03
PCT/AU2006/000750 WO2006128245A1 (en) 2005-06-03 2006-06-02 Targeting cells with altered microrna expression

Publications (2)

Publication Number Publication Date
EP1904110A1 EP1904110A1 (de) 2008-04-02
EP1904110A4 true EP1904110A4 (de) 2009-02-11

Family

ID=37481150

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11161737A Withdrawn EP2377559A1 (de) 2005-06-03 2006-06-02 Targeting von Zellen mit veränderter microRNA-Expression
EP06741167A Withdrawn EP1904110A4 (de) 2005-06-03 2006-06-02 Targeting von zellen mit veränderter microrna-expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11161737A Withdrawn EP2377559A1 (de) 2005-06-03 2006-06-02 Targeting von Zellen mit veränderter microRNA-Expression

Country Status (5)

Country Link
EP (2) EP2377559A1 (de)
JP (1) JP2008541737A (de)
AU (1) AU2006254732A1 (de)
CA (1) CA2610702A1 (de)
WO (1) WO2006128245A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2572450A1 (en) 2004-05-28 2005-12-15 Ambion, Inc. Methods and compositions involving microrna
EP2302055B1 (de) 2004-11-12 2014-08-27 Asuragen, Inc. Verfahren und Zusammensetzungen, die miRNAs und miRNAa-inhibitorischen Molekülen verbunden sind
EP2046970B2 (de) † 2006-08-04 2020-04-29 Dublin City University Verfahren zur herstellung rekombinanter biologischer produkte
EP2145001A2 (de) * 2006-09-19 2010-01-20 Asuragen, Inc. Von mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulierte gene und stoffwechselwege als ziele für einen therapeutischen eingriff
CA2663812A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-143 regulated genes and pathways as targets for therapeutic intervention
CA2663878A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2008036765A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
JP2010516249A (ja) * 2007-01-17 2010-05-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 腫瘍治療のためのミクロｒｎａに関する組成物及び方法
EP2136846A4 (de) * 2007-03-26 2011-04-13 Crc For Asthma And Airways Ltd Therapeutische ziele und moleküle
US20100113577A1 (en) * 2007-04-11 2010-05-06 Bin Shi Isolated nucleic acid molecules corresponding to micro rna 145 (mirna-145) and their use in treating colon cancer
US20100204309A1 (en) * 2007-04-19 2010-08-12 Vib Vzw Oligonucleotide compositions for the treatment of alzheimer's disease
JP5587777B2 (ja) 2007-07-31 2014-09-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 線維症をモジュレートするマイクロｒｎａファミリー及びその使用
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
JP2009100687A (ja) * 2007-10-24 2009-05-14 Chiba Univ ｍｉｃｒｏＲＮＡ発現プロファイリングに基づく膀胱癌の検出方法
JP5737935B2 (ja) * 2008-03-27 2015-06-17 雅彦 黒田 乳癌判定用のマーカーおよび検査方法
EP2112235A1 (de) * 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Zusammensetzungen und Verfahren zur microRNA-Expressionsprofilierung von Nasenrachenkrebs
EP2990487A1 (de) 2008-05-08 2016-03-02 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
CN102099472A (zh) * 2008-05-19 2011-06-15 新加坡科技研究局 使基因表达靶向于神经胶质瘤的核酸分子和方法
WO2010075101A2 (en) * 2008-12-15 2010-07-01 Dcb-Usa, Llc Treating picornavirus infection by targeting microrna mir-141
SI2424571T1 (sl) 2009-04-30 2020-10-30 Ospedale San Raffaele S.R.L. Genski vektor
WO2010135714A2 (en) * 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
EP2341145A1 (de) * 2009-12-30 2011-07-06 febit holding GmbH miRNA-Fingerabdruck für die Krankheitsdiagnose
WO2011111715A1 (ja) * 2010-03-09 2011-09-15 協和発酵キリン株式会社 細胞周期を制御する核酸
WO2011112732A2 (en) * 2010-03-12 2011-09-15 The Brigham And Women's Hospital, Inc. Methods of treating vascular inflammatory disorders
WO2012005339A1 (ja) * 2010-07-08 2012-01-12 武田薬品工業株式会社 糖尿病の予防・治療剤
US9222085B2 (en) 2011-02-03 2015-12-29 Mirna Therapeutics, Inc. Synthetic mimics of MIR-124
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
JP5704576B2 (ja) * 2012-12-28 2015-04-22 国立大学法人 千葉大学 ｍｉｃｒｏＲＮＡ発現プロファイリングに基づく膀胱癌の検出方法
JP5704575B2 (ja) * 2012-12-28 2015-04-22 国立大学法人 千葉大学 ｍｉｃｒｏＲＮＡ発現プロファイリングに基づく膀胱癌の検出方法
JP5812361B2 (ja) * 2013-07-11 2015-11-11 国立研究開発法人医薬基盤・健康・栄養研究所 遺伝子発現制御機構を含む新規Ａｄベクター
CN104120128B (zh) * 2014-07-02 2016-04-20 重庆贝羿生物科技有限公司 一种用于促进vhl基因表达的分离的核苷酸分子和促进剂及其制备
CN104726500B (zh) * 2015-03-12 2017-09-12 中国人民解放军第二军医大学 MicroRNA26b‑3p抑制剂在制备人脐带来源间充质干细胞中的应用
EP3359670B2 (de) 2015-10-05 2024-02-14 ModernaTX, Inc. Verfahren zur therapeutischen verabreichung messenger-ribonukleinsäure-arzneimitteln
US11293065B2 (en) 2016-03-14 2022-04-05 Aelan Cell Technologies, Inc. Compositions and methods for the quality control of stem cell preparations
EP3491137A1 (de) * 2016-07-26 2019-06-05 Senti Biosciences, Inc. Raumzeitliche regulatoren
BR112019008810A2 (pt) 2016-11-01 2019-07-16 Univ New York State Res Found micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
GB201805287D0 (en) * 2018-03-29 2018-05-16 Univ Edinburgh Haematoietic stem cell treatment
CA3103267A1 (en) * 2018-06-14 2019-12-19 Ovid Therapeutics Inc. Use of mir-92a or mir-145 in the treatment of angelman syndrome
CN112301033B (zh) * 2020-11-24 2021-11-19 南通大学 miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用
CN113750111A (zh) * 2021-09-23 2021-12-07 清华大学深圳国际研究生院 一种miRNA-15A用于治疗高表达KIF3B肿瘤中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078096A2 (en) * 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1793674B1 (de) * 2003-11-26 2018-05-30 University of Massachusetts Sequenzspezifische hemmung der funktion von kleiner rna
EP2295604B1 (de) * 2004-02-09 2015-04-08 Thomas Jefferson University Krebsdiagnose und Behandlung durch microRNA, die sich in der Nähe von Krebs-verbindenen Chromosom-Merkmale befinden
AU2005243410B2 (en) * 2004-05-14 2010-04-22 Rosetta Genomics Ltd. Micronas and uses thereof
CN101031658A (zh) * 2004-05-26 2007-09-05 罗塞塔金诺米克斯有限公司 病毒和病毒相关mirna及其用途
CA2609142C (en) * 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078096A2 (en) * 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHN BINO ET AL: "Human MicroRNA targets.", PLOS BIOLOGY NOV 2004, vol. 2, no. 11, November 2004 (2004-11-01), pages e363, XP009109996, ISSN: 1545-7885 *
MANSFIELD JENNIFER H ET AL: "MicroRNA-responsive 'sensor' transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, vol. 36, no. 10, 1 October 2004 (2004-10-01), pages 1079 - 1083, XP002394622, ISSN: 1061-4036 *
See also references of WO2006128245A1 *

Also Published As

Publication number Publication date
AU2006254732A1 (en) 2006-12-07
EP2377559A1 (de) 2011-10-19
EP1904110A1 (de) 2008-04-02
CA2610702A1 (en) 2006-12-07
JP2008541737A (ja) 2008-11-27
WO2006128245A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
EP1904110A4 (de) Targeting von zellen mit veränderter microrna-expression
IL197444A0 (en) Cell culture improvements
GB2424118B (en) Fuel cells
GB0720484D0 (en) Cells
EP2033230A4 (de) Solarzellenanordnung
GB2440434B (en) Fuel cells
GB2438352B (en) Cell culture chamber
EP1979951A4 (de) Solarzelle
GB0605878D0 (en) Fuel cells
GB0608079D0 (en) Fuel cells
GB0714048D0 (en) Fuel cells
EP2095430A4 (de) Solarzelle
EP2200112A4 (de) Zellenanordnung
EP2028264A4 (de) Zellinkubator
GB0517382D0 (en) Cell culture
EP2118278A4 (de) Gezielte genmodifikation bei stammzellen
EP2095405A4 (de) Solarzellen
GB2440366B (en) Solar cells
EP2192402A4 (de) Enzymelektrode
EP1723139A4 (de) Zellbindende konjugate
GB0503918D0 (en) Cell
GB0601101D0 (en) Solar cell
GB0522564D0 (en) Cells
GB0600960D0 (en) Whole cell biosensor
GB0602082D0 (en) Cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090114

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/48 20060101ALI20090108BHEP

Ipc: C12N 15/11 20060101ALI20090108BHEP

Ipc: A61K 48/00 20060101AFI20070202BHEP

Ipc: C12Q 1/68 20060101ALI20090108BHEP

Ipc: A61P 35/00 20060101ALI20090108BHEP

17Q First examination report despatched

Effective date: 20090401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120323